Expression and prognostic relevance of MAGE-A3 and MAGE-C2 in non-small cell lung cancer

Xinfeng Chen; Liping Wang; Jinyan Liu; Lan Huang; Yang Li; Qun Gao; Xiaojuan Shi; Jieyao Li; Feng Li; Zhen Zhang; Song Zhao; Bin Zhang; Pierre van Der Bruggen; Yi Zhang

doi:10.3892/ol.2017.5665

Expression and prognostic relevance of MAGE-A3 and MAGE-C2 in non-small cell lung cancer

Xinfeng Chen, Liping Wang, Jinyan Liu, Lan Huang, Yang Li, Qun Gao, Xiaojuan Shi, Jieyao Li, Feng Li, Zhen Zhang, Song Zhao, Bin Zhang, Pierre van Der Bruggen, Yi Zhang^*

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

43 Scopus citations

Abstract

Melanoma-associated antigen (MAGE)-A3 and MAGE-C2 are antigens encoded by cancer-germline genes, and have been recognized as potential prognostic biomarkers and attractive targets for immunotherapy in multiple types of cancer. The present study aimed to analyze the clinicopathological significance of MAGE-A3/C2 expression in non-small cell lung cancer (NSCLC). The association betweenMAGE-A3/C2mRNA and protein expression, and the pathological characteristics and overall survival of patients with NSCLC was analyzed. In addition, the functional role of MAGE-A3 in human NSCLC cell line A549 was examined in vitro. MAGE-A3/C2 mRNA expression was identified in 73% (151/206) and 53% (109/206) of patients with NSCLC, respectively. MAGE-A3/C2 protein expression was identified in 58% (44/76) and 53% (40/76) of NSCLC cases, respectively. MAGE-A3 mRNA expression was observed to be associated with smoking history, disease stage and lymph node metastasis. However, no association was identified between MAGE-C2 mRNA expression and the clinicopathological characteristics of patients with NSCLC. MAGE-A3/C2-positive patients had a poorer survival rate compared with MAGE-A3/C2-negative patients. Multivariate analysis identified that MAGE-A3 expression may serve as an independent marker of poor prognosis in patients with NSCLC. Downregulation of MAGE-A3 mRNA expression in A549 cells resulted in lower migration and colony formation rates, and a higher amount of epithelial marker and lower amount of mesenchymal marker expression compared with the control group. These results indicate that MAGE-A3 serves a role in NSCLC cell metastasis through the induction of epithelial-mesenchymal transition. In conclusion, MAGE-A3 may serve as a diagnostic and prognostic biomarker for patients with NSCLC, due to its association with tumor progression and poor clinical outcome.

Original language	English (US)
Pages (from-to)	1609-1618
Number of pages	10
Journal	Oncology Letters
Volume	13
Issue number	3
DOIs	https://doi.org/10.3892/ol.2017.5665
State	Published - Mar 2017

Funding

The present study was supported by the China‑US Program for Biomedical Collaborative Research (grant no. 812111102), the National Natural Science Foundation of China (grant no. 81171986), the Ministry of Public Health (grant no. 20110110001), the Basic and Advanced Technology Research Foundation of the Science and Technology Department of Henan Province (grant nos. 112300410153 and 122300410155).

Keywords

Cancer-germline genes
Epithelial-mesenchymal transition
Non-small cell lung cancer
Prognostic biomarker

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3892/ol.2017.5665

Cite this

@article{1dc8fc047c90478fa1cf425f6255ad75,

title = "Expression and prognostic relevance of MAGE-A3 and MAGE-C2 in non-small cell lung cancer",

abstract = "Melanoma-associated antigen (MAGE)-A3 and MAGE-C2 are antigens encoded by cancer-germline genes, and have been recognized as potential prognostic biomarkers and attractive targets for immunotherapy in multiple types of cancer. The present study aimed to analyze the clinicopathological significance of MAGE-A3/C2 expression in non-small cell lung cancer (NSCLC). The association betweenMAGE-A3/C2mRNA and protein expression, and the pathological characteristics and overall survival of patients with NSCLC was analyzed. In addition, the functional role of MAGE-A3 in human NSCLC cell line A549 was examined in vitro. MAGE-A3/C2 mRNA expression was identified in 73% (151/206) and 53% (109/206) of patients with NSCLC, respectively. MAGE-A3/C2 protein expression was identified in 58% (44/76) and 53% (40/76) of NSCLC cases, respectively. MAGE-A3 mRNA expression was observed to be associated with smoking history, disease stage and lymph node metastasis. However, no association was identified between MAGE-C2 mRNA expression and the clinicopathological characteristics of patients with NSCLC. MAGE-A3/C2-positive patients had a poorer survival rate compared with MAGE-A3/C2-negative patients. Multivariate analysis identified that MAGE-A3 expression may serve as an independent marker of poor prognosis in patients with NSCLC. Downregulation of MAGE-A3 mRNA expression in A549 cells resulted in lower migration and colony formation rates, and a higher amount of epithelial marker and lower amount of mesenchymal marker expression compared with the control group. These results indicate that MAGE-A3 serves a role in NSCLC cell metastasis through the induction of epithelial-mesenchymal transition. In conclusion, MAGE-A3 may serve as a diagnostic and prognostic biomarker for patients with NSCLC, due to its association with tumor progression and poor clinical outcome.",

keywords = "Cancer-germline genes, Epithelial-mesenchymal transition, Non-small cell lung cancer, Prognostic biomarker",

author = "Xinfeng Chen and Liping Wang and Jinyan Liu and Lan Huang and Yang Li and Qun Gao and Xiaojuan Shi and Jieyao Li and Feng Li and Zhen Zhang and Song Zhao and Bin Zhang and {van Der Bruggen}, Pierre and Yi Zhang",

note = "Funding Information: The present study was supported by the China‑US Program for Biomedical Collaborative Research (grant no. 812111102), the National Natural Science Foundation of China (grant no. 81171986), the Ministry of Public Health (grant no. 20110110001), the Basic and Advanced Technology Research Foundation of the Science and Technology Department of Henan Province (grant nos. 112300410153 and 122300410155). Publisher Copyright: {\textcopyright} 2017, Spandidos Publications. All rights reserved.",

year = "2017",

month = mar,

doi = "10.3892/ol.2017.5665",

language = "English (US)",

volume = "13",

pages = "1609--1618",

journal = "Oncology Letters",

issn = "1792-1074",

publisher = "Spandidos Publications",

number = "3",

}

TY - JOUR

T1 - Expression and prognostic relevance of MAGE-A3 and MAGE-C2 in non-small cell lung cancer

AU - Chen, Xinfeng

AU - Wang, Liping

AU - Liu, Jinyan

AU - Huang, Lan

AU - Li, Yang

AU - Gao, Qun

AU - Shi, Xiaojuan

AU - Li, Jieyao

AU - Li, Feng

AU - Zhang, Zhen

AU - Zhao, Song

AU - Zhang, Bin

AU - van Der Bruggen, Pierre

AU - Zhang, Yi

N1 - Funding Information: The present study was supported by the China‑US Program for Biomedical Collaborative Research (grant no. 812111102), the National Natural Science Foundation of China (grant no. 81171986), the Ministry of Public Health (grant no. 20110110001), the Basic and Advanced Technology Research Foundation of the Science and Technology Department of Henan Province (grant nos. 112300410153 and 122300410155). Publisher Copyright: © 2017, Spandidos Publications. All rights reserved.

PY - 2017/3

Y1 - 2017/3

N2 - Melanoma-associated antigen (MAGE)-A3 and MAGE-C2 are antigens encoded by cancer-germline genes, and have been recognized as potential prognostic biomarkers and attractive targets for immunotherapy in multiple types of cancer. The present study aimed to analyze the clinicopathological significance of MAGE-A3/C2 expression in non-small cell lung cancer (NSCLC). The association betweenMAGE-A3/C2mRNA and protein expression, and the pathological characteristics and overall survival of patients with NSCLC was analyzed. In addition, the functional role of MAGE-A3 in human NSCLC cell line A549 was examined in vitro. MAGE-A3/C2 mRNA expression was identified in 73% (151/206) and 53% (109/206) of patients with NSCLC, respectively. MAGE-A3/C2 protein expression was identified in 58% (44/76) and 53% (40/76) of NSCLC cases, respectively. MAGE-A3 mRNA expression was observed to be associated with smoking history, disease stage and lymph node metastasis. However, no association was identified between MAGE-C2 mRNA expression and the clinicopathological characteristics of patients with NSCLC. MAGE-A3/C2-positive patients had a poorer survival rate compared with MAGE-A3/C2-negative patients. Multivariate analysis identified that MAGE-A3 expression may serve as an independent marker of poor prognosis in patients with NSCLC. Downregulation of MAGE-A3 mRNA expression in A549 cells resulted in lower migration and colony formation rates, and a higher amount of epithelial marker and lower amount of mesenchymal marker expression compared with the control group. These results indicate that MAGE-A3 serves a role in NSCLC cell metastasis through the induction of epithelial-mesenchymal transition. In conclusion, MAGE-A3 may serve as a diagnostic and prognostic biomarker for patients with NSCLC, due to its association with tumor progression and poor clinical outcome.

AB - Melanoma-associated antigen (MAGE)-A3 and MAGE-C2 are antigens encoded by cancer-germline genes, and have been recognized as potential prognostic biomarkers and attractive targets for immunotherapy in multiple types of cancer. The present study aimed to analyze the clinicopathological significance of MAGE-A3/C2 expression in non-small cell lung cancer (NSCLC). The association betweenMAGE-A3/C2mRNA and protein expression, and the pathological characteristics and overall survival of patients with NSCLC was analyzed. In addition, the functional role of MAGE-A3 in human NSCLC cell line A549 was examined in vitro. MAGE-A3/C2 mRNA expression was identified in 73% (151/206) and 53% (109/206) of patients with NSCLC, respectively. MAGE-A3/C2 protein expression was identified in 58% (44/76) and 53% (40/76) of NSCLC cases, respectively. MAGE-A3 mRNA expression was observed to be associated with smoking history, disease stage and lymph node metastasis. However, no association was identified between MAGE-C2 mRNA expression and the clinicopathological characteristics of patients with NSCLC. MAGE-A3/C2-positive patients had a poorer survival rate compared with MAGE-A3/C2-negative patients. Multivariate analysis identified that MAGE-A3 expression may serve as an independent marker of poor prognosis in patients with NSCLC. Downregulation of MAGE-A3 mRNA expression in A549 cells resulted in lower migration and colony formation rates, and a higher amount of epithelial marker and lower amount of mesenchymal marker expression compared with the control group. These results indicate that MAGE-A3 serves a role in NSCLC cell metastasis through the induction of epithelial-mesenchymal transition. In conclusion, MAGE-A3 may serve as a diagnostic and prognostic biomarker for patients with NSCLC, due to its association with tumor progression and poor clinical outcome.

KW - Cancer-germline genes

KW - Epithelial-mesenchymal transition

KW - Non-small cell lung cancer

KW - Prognostic biomarker

UR - http://www.scopus.com/inward/record.url?scp=85011924560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011924560&partnerID=8YFLogxK

U2 - 10.3892/ol.2017.5665

DO - 10.3892/ol.2017.5665

M3 - Article

C2 - 28454298

AN - SCOPUS:85011924560

SN - 1792-1074

VL - 13

SP - 1609

EP - 1618

JO - Oncology Letters

JF - Oncology Letters

IS - 3

ER -

Expression and prognostic relevance of MAGE-A3 and MAGE-C2 in non-small cell lung cancer

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this